<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04302103</url>
  </required_header>
  <id_info>
    <org_study_id>18C011</org_study_id>
    <nct_id>NCT04302103</nct_id>
  </id_info>
  <brief_title>A Study of TACI（Transmembrane Activator and Calcium-modulator and Cyclophilin Ligand (CAML) Interactor）-Antibody Fusion Protein Injection (RC18) in Subjects With Systemic Myasthenia Gravis</brief_title>
  <official_title>A Study of RC18, a Recombinant Human B Lymphocyte Stimulator Receptor:Immunoglobulin G( IgG ) Fc Fusion Protein for Injection for the Treatment of Subjects With Systemic Myasthenia Gravis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>RemeGen Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>RemeGen Co., Ltd.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to initially observe the safety and effectivity of RC18 in&#xD;
      Participants with systemic myasthenia gravis.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 7, 2020</start_date>
  <completion_date type="Anticipated">December 2021</completion_date>
  <primary_completion_date type="Anticipated">October 2021</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The average variation of QMG scores of the twenty-fourth week compared to the QMG scores of baseline</measure>
    <time_frame>week 24</time_frame>
    <description>QMG score=Quantitative Myasthenia Gravis Score</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>The average variation of clinical absolute score for myasthenia gravis of the twelfth and twenty-fourth weeks compared to Clinical absolute score for myasthenia gravis of baseline</measure>
    <time_frame>week 12，24</time_frame>
    <description>It is best that the assessors in each center are fixed during the study.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The average variation of QMG score of the twelfth week compared to the OMG scores of baseline</measure>
    <time_frame>week 12</time_frame>
    <description>QMG score=Quantitative Myasthenia Gravis Score</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Systemic Myasthenia Gravis</condition>
  <arm_group>
    <arm_group_label>RC18 160mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients received the test group RC18 160mg weekly administered subcutaneously for 24 times.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>RC18 240 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients received the test group RC18 240mg weekly administered subcutaneously for 24 times.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>RC18 160mg</intervention_name>
    <description>subcutaneous injection</description>
    <arm_group_label>RC18 160mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>RC18 240 mg</intervention_name>
    <description>subcutaneous injection</description>
    <arm_group_label>RC18 240 mg</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Voluntarily signed informed consent ;&#xD;
&#xD;
          2. Patient diagnosed with systemic myasthenia gravis according to The following&#xD;
             conditions.&#xD;
&#xD;
          3. Seropositive at screening for AChR（Acetylcholine receptor）-Ab or MuSK（Muscle specific&#xD;
             tyrosine kinase）-Ab;&#xD;
&#xD;
          4. MGFA（Myasthenia Gravis Foundation of America） Clinical classification Ⅱ-IIIb;&#xD;
&#xD;
          5. QMG score≥8,and QMG score&gt;2 in four or more items;&#xD;
&#xD;
          6. Maintained any one of the stable standard treatment programs in the trial protocol.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Combined autoimmune diseases, such as systemic lupus erythematosus,rheumatoid&#xD;
             arthritis, systemic sclerosis and so on,except for hypothyroidism and hyperthyroidism;&#xD;
&#xD;
          2. Abnormal laboratory parameters need to be excluded, including but not limited to:&#xD;
&#xD;
          3. Immunosuppressive agents except agents of standard treatment programs were used within&#xD;
             one month prior to randomization.;&#xD;
&#xD;
          4. Use of biological agents for targeted therapy within 6 months prior to randomization;&#xD;
&#xD;
          5. Intravenous immunoglobulin therapy or plasma exchange therapy within 2 months before&#xD;
             randomization;&#xD;
&#xD;
          6. Active infection during screening(For example,herpes zoster,HIV antibody&#xD;
             positive,active tuberculosis,etc);&#xD;
&#xD;
          7. Currently suffering from active hepatitis or severe liver lesions and history;&#xD;
&#xD;
          8. Diabetics with poor blood sugar control:HbAlc&gt;9.0% or FBG≥11.1mmol/L;&#xD;
&#xD;
          9. Currently having a thymic tumor ,or had a thymectomy within 6 months prior to&#xD;
             screening;&#xD;
&#xD;
         10. Received live vaccines within 3 months before randomization,or scheduled to administer&#xD;
             vaccine during the trial;&#xD;
&#xD;
         11. Malignant tumor patients;&#xD;
&#xD;
         12. Allergic to human biological preparations;&#xD;
&#xD;
         13. Have participated in any clinical trial within 28 days before randomization,or in 5&#xD;
             times half-life period of the drugs of any clinical trial(taking the longer time).&#xD;
&#xD;
         14. Pregnant , lactating women and men or women who have birth plans during the research;&#xD;
&#xD;
         15. Having alcohol or drug abuse that affect the experimental conditions;&#xD;
&#xD;
         16. Investigator considers candidates not appropriating for the study.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Xianhao Xu, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Beijing Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Binghua Xiao</last_name>
    <phone>86-010-58076833</phone>
    <email>Xiaobing.hua@remegen.cn</email>
  </overall_contact>
  <location>
    <facility>
      <name>Beijing Tiantan Hospital,Capital Medical University</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100070</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Xinghu Zhang, M.D.</last_name>
      <phone>010-59976611</phone>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>April 2021</verification_date>
  <study_first_submitted>March 6, 2020</study_first_submitted>
  <study_first_submitted_qc>March 6, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">March 10, 2020</study_first_posted>
  <last_update_submitted>April 22, 2021</last_update_submitted>
  <last_update_submitted_qc>April 22, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">April 26, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Myasthenia Gravis</mesh_term>
    <mesh_term>Muscle Weakness</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

